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T
he UKRussia extracellular vesicles (EVs) work-
shop was held at the Medical Center of the M.V.
Lomonosov Moscow State University, Moscow,
Russia, with 56 attendees from UK and Russian uni-
versities and research institutes. The program consisted of
6 research sessions and was focused on studies of EVs
isolated from in vitro model systems or biological fluids,
including blood and urine. The multidisciplinary pro-
gram included presentations on mechanisms of EV
biogenesis, the role of EVs in disease pathogenesis, the
diagnostic value of EVs, including their quantitation and
cargo load, as well as the clinical use of EVs in rege-
nerative medicine. Methodological challenges imposed by
the nanoscale size of EVs as well as targeted delivery
approaches for therapeutics were considered in a separate
session on technologies. The main aim of the workshop
was to overview challenges confronting EV researchers
and to facilitate knowledge exchange between researchers
with different backgrounds and skills. Given the lack of
definitive EV nomenclature, specific terms (exosomes or
microvesicles) were only applied in the meeting report to
studies that carried out full EV characterization, includ-
ing differential ultracentrifugation isolation approaches,
comprehensive protein marker characterization, and
single vesicle analysis (electron microscopy and nanopar-
ticle analysis), to ascertain EV size and morphology
following the International Society for Extracellular
Vesicles standardization recommendations (1,2). In stu-
dies where characterization was not conclusive, the term
EV is used.
Session 1, ‘‘Extracellular vesicles in cardiovascular
pathologies,’’ gave us an idea of how these different vesicles
might be implicated in the cardiovascular system, as either
markers of pathology, mediators of cellular processes, or
vehicles for delivery of proteins.
In the first talk, C. Shanahan (King’s College London,
London, UK) showed that previously described matrix
vesicles, released by vascular smooth muscle cells in the
vessel wall that initiate pathological calcification, are exo-
somes as defined by their size and morphology, electron
microscopy, proteomic composition, and presence of exo-
some-enriched proteins. Notably, their release was regulated
by sphingomyelin phosphodiesterase 3, suggesting that
inhibition of this pathway may protect against calcification.

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From the same laboratory, A. Kapustin showed that actin
depolymerization and Rho-associated coiled-coil forming
protein serine/threonine kinase (ROCK) activity were also
required for exosome release by vascular smooth muscle cells.
Sean Davidson (University College London, London,
UK) presented data concerning exosomes, isolated from
the plasma by differential ultracentrifugation and thor-
oughly characterized for the presence of exosome-enriched
markers, as well as their size distribution and morphology.
This exciting research showed that such exosomes are able
to protect the heart against ischaemia and reperfusion
injury, such as occurs during a heart attack. Protection
involved heat shock protein 27 (HSP27) phosphoryla-
tion by exosomal HSP70, in response to activation of
Toll-like receptor 4 (TLR4)  part of the innate immune
system. In another study examining the innate immune
response, X. Li (Cambridge University, Cambridge, UK)
showed that lactadherin was able to inhibit activation of
the inflammasome and thereby limit post-ischaemic cere-
bral injury; however, as yet, the role of EVs in this process
has not been explored.
Standing up for the positive role of large-sized EVs, L.
Ayers (Oxford University Hospitals NHS Trust, Oxford,
UK) presented a clinical study in 119 cardiac patients
subject to a dobutamine stress, showing that EV release,
as measured by flow cytometry, only occurs in healthy
patients and not in disease, suggesting this is a protective
normal physiological response. Supporting this potential
protective role, I. Bogachev (Belgorod National Research
University, Belgorod, Russia) showed that in an experi-
mental model of endothelial dysfunction the total number
of EVs was increased after acute dysfunction, but
decreased after chronic dysfunction.
Turning to specific proteins, M. Heck (University of
Edinburgh, Edinburgh, UK) described a fascinating odyssey
of exploration of invadolysin, a serum protease with di-
verse roles in chromosomes and lipid droplets. E. Ferrer
(Cambridge University, Cambridge, UK) showed that
translationally controlled tumour protein is transported
via EVs and contributes to the pathology of pulmonary
arterial hypertension. M. Balatskaya (Lomonosov Moscow
State University, Moscow, Russia) showed that T-cadherin
is released on the surface of human platelet-derived EVs,
attached via a glycosylphosphatidylinositol anchor.
The second session, ‘‘Extracellular vesicles in oncol-
ogy,’’ was focused on the potential role of EVs as cancer
biomarkers. V. Aushev (N.N. Blokhin Russian Cancer
Research Center, Moscow, Russia) reported high levels of
several miRNAs (miR-205, -30b, and others) in tumour-
associated blood-circulating EVs of lung cancer patients,
with some of these miRNAs also selectively secreted by
corresponding cells in vitro. EVs bound to the surface of
blood cells were investigated in a comparative study of
healthy women and breast cancer patients by S. Tamkovich
(Institute of Chemical Biology and Fundamental Medicine,
Novosibirsk, Russia). Healthy women had smaller EVs
(3050 nm vs. 5070 nm), and an overrepresentation of
cancer-specific miRNAs (miR-103, miR-191, miR-195)
found in erythrocyte-bound EVs compared to leukocyte-
bound or plasma-circulating EVs. N. Yunusova (Tomsk
Cancer Research Institute, Tomsk, Russia) reported on the
role of circulating proteasomes, representing a multi-
subunit complex with several proteolytically active sites,
and EVs, providing intracellular and interstitial transfer of
biologically important molecules, in the pathogenesis of
ovarian cancer.
Some prospective therapeutic effects of EVs as well as
novel delivery approaches were discussed in the third
session, ‘‘Extracellular vesicles in tissue regeneration.’’
N. Iraci (University of Cambridge, Cambridge, UK) pre-
sented on cell-to-cell communication mediated by neural
stem-cell-derived EVs in the context of inflammation. This
work identified a novel mechanism of intercellular signal-
ling via recycling of IFN-g through IFNGR1 to activate
Stat1-dependent signalling in target cells. Other topics in
this session included unidirectional exchange of mitochon-
dria from differentiated cells, such as cortical neurons, and
human multipotent mesenchymal stem cells (D. Zorov,
Lomonosov Moscow State University, Moscow, Russia),
where signals either stimulate differentiation or reprogram
metabolism. S. Skaalure (Imperial College London, London,
UK) reported a variety of techniques for regenerative
medicine, including biodegradable scaffolds to deliver cells
to damaged tissues, as well as the use of EVs to deliver
miRNA and therapeutic drugs to cell populations to direct
cellular behaviour. The final speaker, N. Kalinina, focused on
the paracrine role of EVs secreted by human mesenchymal
stromal cells from adipose tissue in controlling angiogenesis
as a therapy to promote tissue regeneration.
Many cells within the immune system release EVs,
including exosomes, which can have either immune acti-
vating or inhibiting properties. Recently, pathogens have
also been shown to release EVs capable of inhibiting
immune responses. In session 4, ‘‘Extracellular vesicles in
immunology and pathogens,’’ L. Smyth (King’s College
London, London, UK) presented her findings on how
exosomes isolated by differential ultracentrifugation
from regulatory T cells (Treg) and defined by their size,
morphology, and protein enrichment can inhibit T cell
responses as well as dendritic cell function. She highlighted
an inhibitory role for the ectoenzyme CD73, as well as
miRNAs, present in Treg exosomes. The theme of miRNA
and EVs was further discussed by R. Crossland (Newcastle
University, Newcastle upon Tyne, UK), who highlighted
a role for EVs in graft-versus-host disease and the use
of EV miRNAs to monitor the onset of this disease.
Lastly, stunning EM images, showing the release of
streams of EVs from bacteria, were presented in 2 talks
by D. Ross and I. Kudryakova (G.K. Skryabin Institute
of Biochemistry and Physiology of Microorganisms,
Alexander N. Kapustin et al.
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Pushchino, Russia), followed by a discussion of why
bacteria release EVs and the effect they may play in
immune modulation.
The first speaker in the session ‘‘Extracellular vesicles in
systemic disorders and nephrology’’ was R. Dragovic
(University of Oxford, Oxford, UK), who presented an
overview of the role of EVs in normal pregnancy and pre-
eclampsia. The syncytiotrophoblast (STB) layer of the
placenta releases both microvesicles and exosomes 
defined based on their sedimentation properties, size, and
protein marker enrichment  into the maternal circulation.
These microvesicles and exosomes carry pro-inflammatory,
anti-angiogenic, and pro-coagulant factors that may con-
tribute to the maternal systemic inflammatory response
observed in pre-eclampsia. Notably, STB exosomes and
microvesicles may differ functionally and show immuno-
suppressive and pro-inflammatory effects, respectively.
Hyperphosphatemia is a well-known cardiovascular risk
factor. N. Abbasian (University of Leicester, Leicester,
UK) reported that elevated phosphate can induce the
formation of procoagulant endothelial EVs through an
elevation of intracellular Pi concentration, which directly
inhibits phosphoprotein phosphatases, triggering a global
increase in phosphorylation and cytoskeletal changes. W.
Oosthuyzen and E. Morrison (University of Edinburgh,
Edinburgh, UK) presented a new mechanism of inter-
cellular signalling within the kidney and showed that EVs
can be internalised by collecting duct cells, with this uptake
regulated by a vasopressin/V2 receptor-mediated process
of clathrin-dependent endocytosis. Interestingly, the site
of vasopressin action was shown to be basolateral, but
EV uptake was from both apical and basolateral compart-
ments. Normal human urinary exosomes were the subject
of T. Gracia’s talk (University of Cambridge, Cambridge,
UK). She showed enrichment for innate immune proteins
in exosomes isolated from urine by differential ultracen-
trifugation, including antimicrobial proteins and bacterial
and viral receptors, and that urinary exosomes potently
inhibit growth of uropathogenic and commensal E. coli
and induce bacterial lysis. A repertoire of microRNAs
has also been identified in urinary exosomes, raising spec-
ulation around their potential as biomarkers and targets for
treatment. Finally, G. Sharonov (Lomonosov Moscow State
University, Moscow, Russia) elegantly discussed the effects
of receptor clustering within microdomains of the plasma
membrane. He showed that small clusters facilitate signal
transduction whereas intermediate clusters anchor actomyo-
sin fibres to the membrane and promote EV budding.
Session 6, ‘‘Modern technologies to study extracellular
vesicles,’’ featured novel technologies used to study nano-
sized objects. S. Bertazzo (Imperial College London,
London, UK) highlighted how various electron and
light microscopy techniques could be superimposed to
provide new insights into EV biogenesis. E. Khomyakova
(Research Institute of Physical-Chemical Medicine,
Moscow, Russia) discussed theoretical considerations as
well as experimental results comparing differential ultra-
centrifugation to rate-zonal centrifugation using a sucrose
gradient for the purpose of optimizing EV isolation. D.
Ter-Ovanesyan (Harvard University, Cambridge, MA,
USA) presented his work on high-throughput RNA
sequencing of exosomes isolated by differential ultracen-
trifugation from cell media and recent applications to
the profiling of RNAs. V. Burdakov (Petersburg Nuclear
Physics Institute, St Petersburg, Russia) presented work on
the use of EVas a drug delivery vehicle for short interfering
RNAs. E. Evtushenko (Moscow State University, Moscow,
Russia) discussed his work on optimizing the NanoSight
Nanoparticle Tracking Analysis instrument (Malvern
Instruments Ltd, Malvern, United Kingdom) to give
quantitative and reproducible measurements of EV size
and abundance. I. Pintre (University of Manchester,
Manchester, UK) presented her work on the synthesis of
new bio-inspired nanoparticles for drug delivery. Finally,
J. Welsh (University of Southampton, Southampton, UK)
discussed advances in using flow cytometry to analyze
single EVs and highlighted important considerations in
optimizing flow cytometers for this purpose.
In conclusion, the meeting highlighted that EVs are
implicated in avarietyof normal and pathological processes,
from protecting prokaryotic cells to the delivery of a wide
range of cargos that improve or deteriorate systemic or
local pathological conditions. Circulating EVs are attractive
non-invasive diagnostic markers, potentially predictive of
cardiovascular disease, cancer, renal disease, systemic
conditions, or immune responses, with specific subsets of
EVs, or their cargos, elevated in pathological conditions.
Data presented about combinations of EVs capable of
stimulating biological effects and local controlled delivery
approaches put a focus on EVs as prospective tools in
regenerative medicine. Yet, despite these promising clini-
cal applications, questions addressing why and how cells
release EVs remain poorly investigated and require further
multidisciplinary and innovative studies.
Acknowledgements
This workshop was jointly supported by a Researcher Links Grant
from the British Council and a grant from the Russian Foundation
of Basic Research (Project No 14-54-77003) to ANK and VT.
References
1. Gould SJ, Raposo G. As we wait: coping with an imperfect
nomenclature for extracellular vesicles. J Extracell Vesicles.
2013;2:20389, doi: http://dx.doi.org/10.3402/jev.v2i0.20389
2. Lo¨tvall J, Hill AF, Hochberg F, Buza´s EI, Di Vizio D, Gardiner
C, et al. Minimal experimental requirements for definition of
extracellular vesicles and their functions: a position statement
from the International Society for Extracellular Vesicles. J
Extracell Vesicles. 2014;3:26913, doi: http://dx.doi.org/10.3402/
jev.v3.26913
UKRussia Researcher Links Workshop
Citation: Journal of Extracellular Vesicles 2015, 4: 28094 - http://dx.doi.org/10.3402/jev.v4.28094 3
(page number not for citation purpose)
